Etigilimab is under clinical development by Mereo Biopharma Group and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Etigilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Etigilimab overview

Etigilimab (OMP-313M32) is under development for the treatment of advanced or metastatic solid tumors includes sarcoma, uveal melanoma, germ cell cancer, epithelial ovarian cancer, peritoneal cancer and fallopian tube cancer, head and neck cancer, adenocarcinoma of the gastroesophageal junction, esophageal cancer, gastric cancer, cervical cancer, triple negative breast cancer, endometrial cancer, pancreatic cancer, anal cancer, hepatocellular cancer, colorectal cancer and non-small cell lung cancer. It is administered intravenously. The therapeutic candidate is an IgG1 monoclonal antibody. It acts by targeting TIGIT.

Mereo Biopharma Group overview

Mereo Biopharma Group is a specialty biopharmaceutical company. The company develops novel medicines for the treatment of rare and specialty diseases. Its pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome and BCT-197, and Etigilimab (MPH-313), which treats solid tumors. Mereo Biopharma Group also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotropic hypogonadism and its Navicixizumab (OMP-305B83) treats platinum-resistant ovarian cancer. The company collaborates with biotechnology and pharmaceutical companies. Mereo Biopharma Group is headquartered in London, England, the UK.

For a complete picture of Etigilimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.